Brevan Howard Capital Management’s Emergent Biosolutions EBS Stock Holding History

Brevan Howard Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$271K	Buy	32,613 +22,526	+223%	+$233K	﹤0.01%	1691
2025 Q4	$125K	Sell	10,087 -3,813	-27%	-$40.9K	﹤0.01%	1661
2025 Q3	$123K	Sell	13,900 -4,824	-26%	-$37.5K	﹤0.01%	1842
2025 Q2	$119K	Buy	18,724 +5,743	+44%	+$32.9K	﹤0.01%	1774
2025 Q1	$63.1K	Buy	+12,981	New	+$107K	﹤0.01%	1082
2024 Q3	–	Sell	-29,058	Closed	-$198K	–	1214
2024 Q2	$198K	Buy	+29,058	New	+$125K	﹤0.01%	895
2023 Q4	–	Sell	-13,781	Closed	-$46.9K	–	1036
2023 Q3	$46.9K	Buy	+13,781	New	+$76.4K	﹤0.01%	366

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Brevan Howard Capital Management's EBS Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Emergent Biosolutions (EBS) stake by 223% in Q1 2026, buying an estimated $233K and bringing the position to 32,613 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #1691.

Brevan Howard Capital Management first reported a position in EBS in Q3 2023 and has held it in 7 quarters since. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Brevan Howard Capital Management held 32,613 shares of Emergent Biosolutions worth $271K as of Q1 2026.
Brevan Howard Capital Management bought 22,526 Emergent Biosolutions shares in Q1 2026, an estimated $233K.
Emergent Biosolutions made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1691 holding.
Brevan Howard Capital Management first reported a position in Emergent Biosolutions in Q3 2023 and has held it in 7 quarters since.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.